Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second-generation anti-HCV tests predict infectivity.

J Larsen1, K Skaug, A Maeland

  • 1Blood Bank, Ullevaal Hospital, Oslo, Norway.

Vox Sanguinis
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Offshore solar farms as habitats for Mytilus edulis: A preliminary modelling study on mussel growth, distribution, chlorophyll-a uptake and bio-deposition in the North Sea.

Marine environmental research·2025
Same author

Benomyl inhibits phosphorus transport but not fungal alkaline phosphatase activity in a Glomus-cucumber symbiosis.

The New phytologist·2021
Same author

Use of Crotalidae equine immune F(ab')<sub>2</sub> antivenom for treatment of an <i>Agkistrodon</i> envenomation.

Clinical toxicology (Philadelphia, Pa.)·2021
Same author

Distance to pig farms as risk factor for community-onset livestock-associated MRSA CC398 infection in persons without known contact to pig farms-A nationwide study.

Zoonoses and public health·2018
Same journal

Red cell alloantibodies in 71,525 Malaysian blood donations: Predominance of anti-Mia reflects GP.Mur-associated antigenic diversity.

Vox sanguinis·2026
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
See all related articles

The second-generation hepatitis C antibody test (EIA-II) is more sensitive for identifying infectious blood donors than the first-generation test. Confirm positive results with recombinant immunoblot assay (RIBA-II) to ensure blood safety.

Area of Science:

  • Hepatology
  • Immunology
  • Public Health

Background:

  • Hepatitis C virus (HCV) screening of blood donations is crucial for public health.
  • First-generation antibody tests for HCV (anti-HCV) have limitations in sensitivity and specificity.
  • Evaluating newer diagnostic assays is essential for improving blood safety.

Purpose of the Study:

  • To retrospectively investigate blood donors and recipients for Hepatitis C virus (HCV) infection.
  • To evaluate the diagnostic performance of first- and second-generation anti-HCV tests.
  • To identify infective donors and assess the utility of EIA-II and RIBA-II.

Main Methods:

  • Retrospective analysis of 24 anti-HCV positive blood donors and 88 recipients from 1972-1990.
  • Utilized first-generation (Ortho EIA-I) and second-generation anti-HCV tests (EIA-II).

Related Experiment Videos

  • Confirmed positive results using recombinant immunoblot assay (RIBA-II).

    • Main Results:

    • Second-generation EIA-II identified more likely infective donors (7/7) compared to non-infective donors (3/17).
    • EIA-II detected 48% of infected recipients who were negative by first-generation tests.
    • The second-generation test demonstrated higher sensitivity in identifying HCV infection.

    Conclusions:

    • Second-generation anti-HCV testing (EIA-II) is recommended for screening blood donors due to its superior sensitivity.
    • Positive EIA-II results should be confirmed with RIBA-II.
    • Individuals with positive or inconclusive RIBA-II results should be excluded from blood donation to prevent HCV transmission.